Last updated on July 2019

S 81694 Plus Paclitaxel in Metastatic Breast Cancer


Brief description of study

The purpose of this study is to determine the safety profile, the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of S 81694 in combination with paclitaxel in metastatic breast cancer (mBC) patients, and to investigate the antitumour activity of the combination in metastatic triple negative breast cancer (mTNBC) patients.

Clinical Study Identifier: NCT03411161

Find a site near you

Start Over